Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma
暂无分享,去创建一个
Holger Moch | Ronald Simon | Guido Sauter | H. Moch | G. Sauter | C. Bokemeyer | R. Simon | W. Wilczak | S. Minner | E. Burandt | L. Terracciano | P. Tennstedt | Christian Eichelberg | Carsten Bokemeyer | M. Fisch | C. Eichelberg | Luigi Terracciano | Sarah Minner | Eike Burandt | Pierre Tennstedt | Waldemar Wilczak | Margit Fisch | Dorothea Rump | Dorothea Rump
[1] S. Sone,et al. Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. , 2003, Oncology research.
[2] T. Asano,et al. Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma. , 2004, The Journal of urology.
[3] I. Bassukas,et al. Epidermal growth factor family and renal cell carcinoma: expression and prognostic impact. , 1997, European urology.
[4] R. Figlin,et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] F. Erdoğan,et al. Prognostic significance of morphologic parameters in renal cell carcinoma , 2004, International journal of clinical practice.
[6] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[7] R. Stahel,et al. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma , 2006, Cancer Chemotherapy and Pharmacology.
[8] I. Giannopoulou,et al. Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas , 2008, Breast Cancer Research.
[9] A. Ravaud,et al. Amplification of epidermal growth factor receptor gene in renal cell carcinoma. , 2010, European journal of cancer.
[10] T. Shibata,et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Elisa Rossi,et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.
[12] G. Niehans,et al. Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] A. Hussain,et al. A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell Carcinoma , 2004, Clinical Cancer Research.
[14] M. Bittner,et al. Chromosomal aberrations and gene expression profiles in non-small cell lung cancer. , 2007, Lung cancer.
[15] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[16] A. Gotoh,et al. EGFR mRNA is Upregulated, but Somatic Mutations of the Gene are Hardly Found in Renal Cell Carcinoma in Japanese Patients , 2005, Pharmaceutical Research.
[17] F. Hirsch,et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] F. Waldman,et al. Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. , 1997, Human pathology.
[19] H. Hollema,et al. Expression of Epidermal Growth Factor Receptor (EGFR) and Activated EGFR Predict Poor Response to (Chemo)radiation and Survival in Cervical Cancer , 2009, Clinical Cancer Research.
[20] C. Magi-Galluzzi,et al. The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation. , 2007, Clinical genitourinary cancer.
[21] F. Waldman,et al. EGF‐r gene copy number changes in renal cell carcinoma detected by fluorescence in situ hybridization , 1998, The Journal of pathology.
[22] M. Berger,et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. , 2005, Journal of the National Cancer Institute.
[23] S. Pomer,et al. Concomitant overexpression of the EGFR and erbB‐2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis , 1996, International journal of cancer.
[24] H. Lane,et al. ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.
[25] S. Maeda,et al. Amplification and overexpression of the epidermal growth factor receptor gene in human renal‐cell carcinoma , 1990, International journal of cancer.
[26] B. Ljungberg,et al. Epidermal growth factor receptor gene expression and binding capacity in renal cell carcinoma, in relation to tumor stage, grade and DNA ploidy , 2004, Urological Research.
[27] S. Advani,et al. Proliferating cell nuclear antigen and epidermal growth factor receptor (EGFr) status in renal cell carcinoma patients with polysomy of chromosome 7. , 2001, Cancer genetics and cytogenetics.
[28] P. Stattin,et al. Low Levels of Phosphorylated Epidermal Growth Factor Receptor in Nonmalignant and Malignant Prostate Tissue Predict Favorable Outcome in Prostate Cancer Patients , 2010, Clinical Cancer Research.
[29] M. Kuczyk,et al. Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer. , 2005, Anticancer research.
[30] R. Figlin,et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] J. Baselga,et al. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] F. Waldman,et al. TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe. , 2010, Cancer letters.
[33] R. Klausner,et al. Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[34] W. Samlowski,et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.